Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 11/20 | 0.76 |
| ▸ | NPR1 | P16066 | 1/20 | 0.76 |
| ▸ | CCKAR | P32238 | 9/20 | 0.48 |
| ▸ | CCKBR | P32239 | 9/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30679285 | 0.96 | NRP1 (0.70) | NRP1NPR1CCKARCCKBR | |
| SCHEMBL4572338 | 0.92 | NRP1 (0.65) | NRP1NPR1CCKARCCKBR | |
| SCHEMBL4572299 | 0.90 | NRP1 (0.77) | NRP1NPR1CCKARCCKBR | |
| SCHEMBL4569831 | 0.88 | NRP1 (0.77) | NRP1NPR1 | |
| SCHEMBL29066366 | 0.88 | NRP1 (0.60) | NRP1NPR1CCKARCCKBR | |
| SCHEMBL4572336 | 0.88 | NRP1 (0.72) | NRP1NPR1CCKARCCKBR | |
| SCHEMBL4569863 | 0.87 | NRP1 (0.58) | NRP1NPR1CCKARCCKBR | |
| SCHEMBL4569817 | 0.86 | NRP1 (0.57) | NRP1NPR1 | |
| SCHEMBL4569824 | 0.85 | NRP1 (0.60) | NRP1NPR1 | |
| SCHEMBL4569810 | 0.84 | NRP1 (0.74) | NRP1NPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122580-A1 | METHOD OF TREATING CHRONIC PAIN USING INHIBITOR OF NEUROPILIN-1 (NRP1) AND G ALPHA INTERACTING PROTEIN (GAIP) INTERACTING PROTEIN C-TERMINUS 1 (GIPC1) | NEW YORK UNIVERSITY (US) | 2025-06-12 | — | — | WO | claimed |
| WO-2025122580-A1 | METHOD OF TREATING CHRONIC PAIN USING INHIBITOR OF NEUROPILIN-1 (NRP1) AND G ALPHA INTERACTING PROTEIN (GAIP) INTERACTING PROTEIN C-TERMINUS 1 (GIPC1) | NEW YORK UNIVERSITY (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20240316011-A1 | ANTI-FIBROSIS PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | WEST CHINA SECOND UNIVERSITY HOSPITAL (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-117414430-A | Application of EPCR pathway activator in preparation of anti-fibrosis agent | 四川大学华西第二医院 | 2024-01-19 | — | — | CN | disclosed |
| CN-113952456-B | Application of EPCR pathway activator in preparation of anti-fibrosis agent | 四川大学华西第二医院 | 2023-12-15 | — | — | CN | disclosed |
| EP-4282424-A1 | ANTI-FIBROSIS PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | West China Second University Hospital (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-114452389-B | Anti-fibrosis pharmaceutical composition and application thereof | 四川大学华西第二医院 | 2023-08-25 | — | — | CN | disclosed |
| CN-114452389-A | Anti-fibrosis pharmaceutical composition and application thereof | 四川大学华西第二医院 | 2022-05-10 | — | — | CN | disclosed |
| CN-113952456-A | Application of EPCR (Epoxic-Hydrocarbon receptor) pathway activator in preparation of anti-fibrosis agent | 四川大学华西第二医院 | 2022-01-21 | — | — | CN | disclosed |
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
| US-8158789-B2 | Arginine derivatives with NP-I antagonistic activity | Ark Therapeutics Group Ltd. (GB) | 2012-04-17 | — | — | US | disclosed |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885NPR1 2/4885CCKAR 365/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | NRP1 145/4885NPR1 2/4885CCKAR 365/4885 |
| US-20100022525-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885NPR1 2/4885CCKAR 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.